[HTML][HTML] Guidelines for Canadian bariatric surgical and medical centres: a statement from the Canadian Association of Bariatric Physicians and Surgeons
…, K Reed, N Christou, J Shaban… - Canadian Journal of …, 2022 - ncbi.nlm.nih.gov
The goal of this statement is to offer standardization in bariatric care across Canada, to
provide patients with optimal access to obesity treatment and potentially improve outcomes by …
provide patients with optimal access to obesity treatment and potentially improve outcomes by …
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or …
…, P Joshi, B Lertoft, J Rastam, CC Chow, J Shaban - Clinical …, 2005 - Elsevier
BACKGROUND:: Few large randomized controlled trials have assessed the value of adding
insulin to an oral antidiabetic drug regimen. OBJECTIVE:: This trial compared the efficacy …
insulin to an oral antidiabetic drug regimen. OBJECTIVE:: This trial compared the efficacy …
[HTML][HTML] Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment …
M Brod, P Valensi, JA Shaban, DM Bushnell… - Quality of Life …, 2010 - Springer
Purpose Understanding treatment satisfaction (TS) for diabetes is increasingly important as
treatment options increase. This study examines treatment satisfaction with NovoMix ® 30 in …
treatment options increase. This study examines treatment satisfaction with NovoMix ® 30 in …
Improved glycaemic control with BIAsp 30 in insulin-naive type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE …
…, J Gumprecht, R Kawamori, J Shaban… - … medical research and …, 2009 - Taylor & Francis
Full article: Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients
inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study …
inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study …
Predictors of achieving HbA1c <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study
P Valensi, J Shaban, M Benroubi… - … medical research and …, 2013 - Taylor & Francis
Full article: Predictors of achieving HbA1c <7% and no hypoglycaemia 6 months after initiation
of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study Skip …
of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study Skip …
Cardiac pheochromocytoma presenting during pregnancy
A 25-year-old woman presented at 12 weeks gestation, with symptoms and laboratory
investigations consistent with pheochromocytoma. Imaging modalities available during pregnancy …
investigations consistent with pheochromocytoma. Imaging modalities available during pregnancy …
Predictors of postprandial blood glucose response to biphasic insulin analogue therapy
…, J Gumprecht, R Kawamori, R Ligthelm, J Shaban… - primary care …, 2013 - Elsevier
Biphasic insulin aspart 30 (BIAsp 30) has been shown in randomised controlled trials and
the IMPROVE™ observational study to reduce postprandial blood glucose (PPBG) – thought …
the IMPROVE™ observational study to reduce postprandial blood glucose (PPBG) – thought …
Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients …
…, J Gumprecht, R Kawamori, J Shaban… - … Journal of Clinical …, 2009 - Wiley Online Library
Aims: The IMPROVE™ observational study evaluated the safety profile and effectiveness of
biphasic insulin aspart 30/70 (BIAsp 30) in patients with type 2 diabetes in routine practice in …
biphasic insulin aspart 30/70 (BIAsp 30) in patients with type 2 diabetes in routine practice in …
[CITATION][C] Peri-operative task force recommendations
J Shaban, M Tiboni, SA Glazer, VT Chetty - Ontario Bariatric Network, 2016
[CITATION][C] NovoMix (R) 30 (BIAsp 30) improves glycemic control in type 2 diabetes: Results from the IMPROVE (TM) study
J Shaban, JB Hansen, Y Wenying - DIABETES, 2008 - AMER DIABETES ASSOC 1701 N …
